(Reuters) -Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year. A key patent for Stelara expired in the United States last year, but J&J struck deals with competitors to delay the launches of their biosimilars until 2025. Analysts have said the delay in biosimilar launches would make Stelara a larger contributor to J&J's 2024 and 2025 sales than previously anticipated.
Results confirmed the long-term efficacy of ustekinumab maintenance in patients with ulcerative colitis, demonstrating consistent rates of symptomatic remission and endoscopic improvement with no new safety signals.
If your moderate to severe crohn s disease or ulcerative colitis symptoms are stopping you in your tracks. choose stelara® from the start. and move toward relief after the first dose. with injections every two months. stelara® may increase your risk of infections, some serious, and cancer. before treatment, get tested for tb. tell your doctor if you have an infection, flu-like symptoms, sores, new skin growths, have had cancer, or if you need a vaccine. pres, a rare, potentially fatal brain condition, may be possible. some serious allergic reactions and lung inflammation can occur. feel unstoppable. ask your doctor how lasting remission can start with stelara®. janssen can help you explore cost support options.
In the last month, there has been a flurry of activity at the PTAB related to challenges from biosimilar manufacturers related to ustekinumab, aflibercept, and eculizumab patents.
More after this. when they can enjoy the best? eggland s best. the only eggs with more fresh and delicious taste. plus, superior nutrition. because the way we care is anything but ordinary. if your moderate to severe crohn s disease or ulcerative colitis symptoms are stopping you in your tracks. choose stelara® from the start. and move toward relief after the first dose. with injections every two months. stelara® may increase your risk of infections, some serious, and cancer. before treatment, get tested for tb. tell your doctor if you have an infection, flu-like symptoms, sores, new skin growths, have had cancer, or if you need a vaccine. pres, a rare, potentially fatal brain condition, may be possible. some serious allergic reactions and lung inflammation can occur. feel unstoppable. ask your doctor how lasting remission can start with stelara®. janssen can help you explore cost support options.
Before treatment, get tested for tb. tell your doctor if you have an infection, flu-like symptoms, sores, new skin growths, have had cancer, or if you need a vaccine. pres, a rare, potentially fatal brain condition, may be possible. some serious allergic reactions and lung inflammation can occur. feel unstoppable. ask your doctor how lasting remission can start with stelara®. janssen can help you explore cost support options. want the power of 5 serum benefits in 1? olay super serum activates on skin to hydrate, smooth, visibly firm, brighten, and improve texture. it s my best skin yet. olay
With hamas confirming the commander of the military wing in the west bank was killed in a drone strik lt night in the suburb of beirut, claiming israel for the attack. he was a key figure who had helped repair the group s relationship with iran. while not confirming israeli authorization of the strike, adviser to prime minister netanyahu mark r told msnbc earlier today the strike was, quote, a surgical hit on hamas. this comes as israel postpones a full israeli cabinet meeting meant to discuss plans for a post hamas gaza. i ll keep you updated as we learn more. up next for us, breaking in just the last few minutes, trump responding to that ruling in maine that keeps him off the ballot as the pressure mounts on the supreme court to act. that breaking news in just a moment. act that breaking news in just a moment and move toward relief after the first dose. with injections every two months. stelara® may increase your risk of infections, some serious, and cancer.
While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.